IgM multiple myeloma with an extremely rare non‑aggressive presentation: A case report

Greuter,Thomas; Browne,Martin; Dommann‑Scherrer,Corina; Binder,Daniel; Renner,Christoph; Kapp,Ursula

doi:10.3892/ol.2016.5034

IgM multiple myeloma with an extremely rare non‑aggressive presentation: A case report

Authors:
- Thomas Greuter
- Martin Browne
- Corina Dommann‑Scherrer
- Daniel Binder
- Christoph Renner
- Ursula Kapp
View Affiliations

Affiliations: Department of Medicine, GZO‑Zurich Regional Health Center, 8620 Wetzikon, Zurich, Switzerland, North Coast Cancer Institute, Coffs Harbour Health Campus, Coffs Harbour, New South Wales 2450, Australia, Division of Hematology, Cantonal Hospital Winterthur, 8401 Winterthur, Zurich, Switzerland, Oncology Centre, Hirslanden Clinic, 8032 Zurich, Switzerland
Published online on: August 17, 2016 https://doi.org/10.3892/ol.2016.5034
Pages: 2801-2803

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the case of a 41‑year‑old man with immunoglobulin (Ig)M multiple myeloma (MM) that presented with an unusually non‑aggressive clinical course who has survived for >9 years to date, is presented. Initial diagnosis of symptomatic MM was established according to the International Myeloma Working Group consensus statement and guidelines. Due to the mild symptoms, no therapy was administered and the patient was closely followed up. Eight years after initial diagnosis, clinical, morphological and genetic progression occurred with the development of hypercalcemia, progressively deteriorating polyneuropathy, clonal expansion of plasma cells up to 50% of hematopoietic cells and demonstration of the typical t(11;14) translocation (Ig heavy chain locus rearrangement). Subsequently, 4 cycles of induction chemotherapy with velcade, cyclophosphamide and dexamethasone, were administered. At the time of writing, the patient remained alive in generally good health. To the best of our knowledge, with a survival time of >9 years, this case reports the longest survival time of an IgM MM patient to date, which contradicts previous evidence that suggests IgM MM exhibits an aggressive clinical course.

View Figures

View References

1	Kyle RA and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kyle RA: Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 6:347–358. 1992.PubMed/NCBI
3	Boccadoro M and Pileri A: Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am. 11:111–131. 1997. View Article : Google Scholar : PubMed/NCBI
4	DeGramont A, Grosbois B, Michaux JL, Peny AM, Pollet JP, Smadja N, Krulik M, Debray J, Bernard JF and Monconduit M: IgM myeloma: 6 cases and a review of the literature. Rev Med Interne. 11:13–18. 1990.(In French). PubMed/NCBI
5	Dierlamm T, Laack E, Dierlamm J, Fiedler W and Hossfeld DK: IgM myeloma: A report of four cases. Ann Hematol. 81:136–139. 2002. View Article : Google Scholar : PubMed/NCBI
6	Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P and Dalakas M: Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol. 18:214–226. 2000.PubMed/NCBI
7	Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R and Mikhael J: IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol. 85:853–855. 2010. View Article : Google Scholar : PubMed/NCBI
8	Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, et al: IMWG: International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 23:1545–1556. 2009. View Article : Google Scholar : PubMed/NCBI
9	Annibali O, Petrucci MT, Del Bianco P, Gallucci C, Levi A, Foà R and Avvisati G: IgM multiple myeloma: Report of four cases and review of the literature. Leuk Lymphoma. 47:1565–1569. 2006. View Article : Google Scholar : PubMed/NCBI
10	Haghighi B, Yanagihara R and Cornbleet PJ: IgM myeloma: Case report with immunophenotypic profile. Am J Hematol. 59:302–308. 1998. View Article : Google Scholar : PubMed/NCBI
11	Avet-Loiseau H, Garand R, Lodé L, Harousseau JL and Bataille R: Intergroupe Francophone du Myélome: Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 101:1570–1571. 2003. View Article : Google Scholar : PubMed/NCBI
12	Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, et al: MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 121:2051–2058. 2013. View Article : Google Scholar : PubMed/NCBI
13	Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, et al: Myeloma Subcommittee of Chronic Leukaemia Working Party of EBMT: Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 95:2126–2133. 2010. View Article : Google Scholar : PubMed/NCBI
14	Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M and Dreyling M: ESMO Guidelines Working Group: Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi133–vi137. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF and Melton LJ III: Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 102:3759–3764. 2003. View Article : Google Scholar : PubMed/NCBI